{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:17:06Z","timestamp":1774415826516,"version":"3.50.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.00555","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T05:31:36Z","timestamp":1588829496000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Possible Genetic Determinants of Response to Phenytoin in a Group of Colombian Patients With Epilepsy"],"prefix":"10.3389","volume":"11","author":[{"given":"Carlos Alberto","family":"Calderon-Ospina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jubby Marcela","family":"Galvez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"L\u00f3pez-Cabra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Mart\u00edn","family":"Restrepo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio Anc\u00edzar","family":"Aristiz\u00e1bal-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Velez-van-Meerbeke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Laissue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dora Janeth","family":"Fonseca-Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1136\/bmj.327.7425.1222","article-title":"Joining the DoTS: new approach to classifying adverse drug reactions","volume":"327","author":"Aronson","year":"2003","journal-title":"BMJ"},{"key":"B2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.2165\/00002018-200528100-00003","article-title":"Clarification of terminology in drug safety","volume":"28","author":"Aronson","year":"2005","journal-title":"Drug Saf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e89253","DOI":"10.1371\/journal.pone.0089253","article-title":"Genetic Association Analysis of ATP Binding Cassette Protein Family Reveals a Novel Association of ABCB1 Genetic Variants with Epilepsy Risk, but Not with Drug-Resistance","volume":"9","author":"Balan","year":"2014","journal-title":"PloS One"},{"key":"B4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neulet.2017.01.014","article-title":"Pharmacogenomics in epilepsy","volume":"667","author":"Balestrini","year":"2018","journal-title":"Neurosci. Lett."},{"key":"B5","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/j.1528-1167.2008.01858.x","article-title":"Polymorphism of the MDR1\/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: A meta-analysis","volume":"50","author":"Bournissen","year":"2009","journal-title":"Epilepsia"},{"key":"B6","first-page":"228","article-title":"Neurological toxicity associated with phenytoin in an intermediate metabolizer patient for CYP2C9 enzyme","volume":"20","author":"Calderon-Ospina","year":"2018","journal-title":"Pharm. Care (Esp)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/clpt.2014.159","article-title":"Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing","volume":"96","author":"Caudle","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.2217\/pgs.11.85","article-title":"Pharmacogenomics and epilepsy: the road ahead","volume":"12","author":"Cavalleri","year":"2011","journal-title":"Pharmacogenomics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"858","DOI":"10.5114\/aoms.2013.38679","article-title":"Pattern of adverse events of antiepileptic drugs: results of the aESCAPE study in Poland","volume":"9","author":"Chmielewska","year":"2013","journal-title":"Arch. Med. Sci. AMS"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-017-0801-x","article-title":"Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysis","volume":"17","author":"Chouchi","year":"2017","journal-title":"BMC Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1046\/j.1365-2125.2002.01591.x","article-title":"MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine","volume":"53","author":"Drescher","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1331\/JAPhA.2008.07050","article-title":"Potential roles for pharmacists in pharmacogenetics","volume":"48","author":"El-Ibiary","year":"2008","journal-title":"J. Am. Pharm. Assoc."},{"key":"B13","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","article-title":"Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"16","author":"Feigin","year":"2017","journal-title":"Lancet Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2147\/PGPM.S170515","article-title":"Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients","volume":"11","author":"Galvez","year":"2018","journal-title":"Pharmacogenom. Pers. Med."},{"key":"B15","volume-title":"The NCBI Handbook - NCBI Bookshelf","year":""},{"key":"B16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11910-009-0050-5","article-title":"Bioequivalence of antiepileptic drugs: how close is close enough","volume":"9","author":"Gidal","year":"2009","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.seizure.2010.05.004","article-title":"ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: A systematic review and meta-analysis","volume":"19","author":"Haerian","year":"2010","journal-title":"Seizure"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1073\/pnas.050585397","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"B19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.neulet.2017.01.012","article-title":"Epigenetics in epilepsy","volume":"667","author":"Kobow","year":"2018","journal-title":"Neurosci. Lett."},{"key":"B20","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early Identification of Refractory Epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies: Definition of Drug Resistant Epilepsy","volume":"51","author":"Kwan","year":"2009","journal-title":"Epilepsia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/NEJMra1004418","article-title":"Drug-Resistant Epilepsy","volume":"365","author":"Kwan","year":"2011","journal-title":"N Engl. J. Med."},{"key":"B23","first-page":"3924","article-title":"Associations between the C3435T polymorphism of the ABCB1 gene and drug resistance in epilepsy: a meta-analysis","volume":"7","author":"Lv","year":"2014","journal-title":"Int. J. Clin. Exp."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s00415-017-8394-2","article-title":"Recent advances in epilepsy","volume":"264","author":"Manford","year":"2017","journal-title":"J. Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2217\/bmm.11.94","article-title":"From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource","volume":"5","author":"McDonagh","year":"2011","journal-title":"Biomark Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1212\/WNL.0b013e31822cfc90","article-title":"Incidence of epilepsy: A systematic review and meta-analysis","volume":"77","author":"Ngugi","year":"2011","journal-title":"Neurology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.seizure.2004.12.007","article-title":"A novel SCN1A mutation associated with severe GEFS+ in a large South American pedigree","volume":"14","author":"Pineda-Trujillo","year":"2005","journal-title":"Seizure"},{"key":"B29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1590\/S1020-49892003000700005","article-title":"Estudio neuroepidemiol\u00f3gico nacional (EPINEURO) colombiano","volume":"14","author":"Pradilla","year":"2003","journal-title":"Rev. Panam. Salud. P\u00fablica"},{"key":"B30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.18433\/J3659Z","article-title":"Assessing bioequivalence of antiepileptic drugs: are the current requirements too permissive","volume":"17","author":"Rediguieri","year":"2014","journal-title":"J. Pharm. Pharm. Sci. Publ. Can. Soc. Pharm. Sci. Soc. Can. Sci. Pharm."},{"key":"B31","unstructured":"Table of Pharmacogenomic Biomarkers in Drug Labeling"},{"key":"B32","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/jps.20717","article-title":"MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells","volume":"95","author":"Salama","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"B33","first-page":"538","article-title":"Focusing on the preventability of adverse drug reactions","volume":"27","author":"Schumock","year":"1992","journal-title":"Hosp. Pharm."},{"key":"B34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/PGPM.S108113","article-title":"CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment","volume":"11","author":"Silvado","year":"2018","journal-title":"Pharmacogenom. Pers. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1111\/j.1528-1167.2007.01260_1.x","article-title":"Drug resistance in epilepsy: more twists in the tale","volume":"48","author":"Sisodiya","year":"2007","journal-title":"Epilepsia"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1528-1167.2011.03121.x","article-title":"Standards for epidemiologic studies and surveillance of epilepsy: Standards for Epidemiologic Studies and Surveillance of Epilepsy","volume":"52","author":"Thurman","year":"2011","journal-title":"Epilepsia"},{"key":"B37","first-page":"249","article-title":"Polimorfismo C3435T del Gen ABCB1 (MDR1) en pacientes con Epilepsia refractaria en tres centros de referencia Nacional en Colombia","volume":"33","author":"Velasco-Parra","year":"","journal-title":"Med. (Bogot\u00e1)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3109\/00207454.2015.1038710","article-title":"Intractable epilepsy and the P-glycoprotein hypothesis","volume":"126","author":"Wang","year":"2016","journal-title":"Int. J. Neurosci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00555\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T05:31:40Z","timestamp":1588829500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00555\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":38,"alternative-id":["10.3389\/fphar.2020.00555"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.00555","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,7]]},"article-number":"555"}}